株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

クローン病 - パイプライン製品の分析

Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232862
出版日 ページ情報 英文 414 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.34円で換算しております。
Back to Top
クローン病 - パイプライン製品の分析 Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2017
出版日: 2017年03月22日 ページ情報: 英文 414 Pages
概要

クローン病は、消化管内壁の炎症であり、人によって病変部位が異なります。主な症状は腹痛、激しい下痢、血便、潰瘍、食欲不振、体重減少などです。

当レポートでは、クローン病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

クローン病の概要

治療薬の開発

クローン病:企業で開発中の治療薬

クローン病:大学/機関で研究中の治療薬

クローン病:パイプライン製品の概況

クローン病:企業で開発中の製品

クローン病:大学/機関で研究中の製品

クローン病の治療薬開発に従事している企業

クローン病:治療薬の評価

薬剤プロファイル

クローン病:最近のパイプライン動向

クローン病:休止中のプロジェクト

クローン病:開発が中止された製品

クローン病:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9074IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2017, provides an overview of the Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline landscape.

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 11, 28, 25, 37, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Crohn's Disease (Regional Enteritis) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Crohn's Disease (Regional Enteritis) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis) (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Regional Enteritis) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Crohn's Disease (Regional Enteritis) - Overview
  • Crohn's Disease (Regional Enteritis) - Therapeutics Development
  • Crohn's Disease (Regional Enteritis) - Therapeutics Assessment
  • Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development
  • Crohn's Disease (Regional Enteritis) - Drug Profiles
  • Crohn's Disease (Regional Enteritis) - Dormant Projects
  • Crohn's Disease (Regional Enteritis) - Discontinued Products
  • Crohn's Disease (Regional Enteritis) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma PLC, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by AB Science SA, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Adello Biologics LLC, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Aerpio Therapeutics Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Alfa Wassermann SpA, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Allergan Plc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Alteogen Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Amgen Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by ARA Healthcare Pvt Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Arena Pharmaceuticals Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Astellas Pharma Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Atlantic Bio Sci LLC, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by BioLingus AG, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by BioTherapeutics Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Calypso Biotech SA, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Celgene Corp, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Cellceutix Corp, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by ChemoCentryx Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by ChironWells GmbH, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by CLL Pharma SA, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Coherus BioSciences Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Commence Bio Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by DBV Technologies SA, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Eisai Co Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Eli Lilly and Company, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Enterome Bioscience SA, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Enzo Biochem Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Ferring International Center SA, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Galapagos NV, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Genentech Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Genor BioPharma Co Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by iCo Therapeutics Inc., H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Iltoo Pharma, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Immune Response BioPharma Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Immune Therapeutics Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Inception Sciences Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Innovent Biologics Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Johnson & Johnson, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Jyant Technologies Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by KPI Therapeutics Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Merck & Co Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Merck KGaA, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Mesoblast Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Momenta Pharmaceuticals Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Mycenax Biotech Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by NeuClone Pty Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Novartis AG, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Oncodesign SA, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Panacea Biotec Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Pfenex Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Protagonist Therapeutics Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Protalix BioTherapeutics Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Qu Biologics Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Re-Pharm Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Sandoz International GmbH, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by SATT North SAS, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Second Genome Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Shire Plc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Sigmoid Pharma Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Soligenix Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Stelic Institute & Co Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Sylentis SAU, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Synedgen Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Synlogic Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Tiziana Life Sciences Plc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Trino Therapeutics Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Ventria Bioscience, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Virobay Inc, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Vivelix Pharmaceuticals Ltd, H1 2017
  • Crohn's Disease (Regional Enteritis) - Pipeline by Xbrane Biopharma AB, H1 2017
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, H1 2017
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Crohn's Disease (Regional Enteritis) - Discontinued Products, H1 2017
  • Crohn's Disease (Regional Enteritis) - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top